Following the recent IPO and the positive Phase 3 clinical data for VDPHL01 (extended-release oral minoxidil), what is the projected timeline for the FDA submission and the subsequent commercial availability on the market? Chat 5/3/2026
Veradermics' extended-release oral minoxidil is expected to be commercially available in 2027-2028, while another company, Minx, may release a similar product sooner. VDPHL01 is considered more clinically validated compared to Minx.
View this post in the Community →
Similar Community Posts Join
5 / 5 resultscommunity Anyone tried Anagen “Smooth Release” oral minoxidil?
People are discussing Anagen's "Smooth Release" oral minoxidil, with some users reporting no side effects or hair growth yet. There are concerns about a potential lawsuit with Veradermics over intellectual property, but no confirmed legal action has been found.
community Veradermics VDPHL01 Topline Results for Extended-Release Oral Minoxidil
Extended-release oral minoxidil (VDPHL01) shows promising results for hair growth with improved safety, achieving significant hair count increases and minimal side effects compared to placebo. The treatment is designed to maintain effective concentrations while reducing side effects, making it a safer option for those who cannot tolerate standard minoxidil.
community Veradermics VDPHL01 Topline Results for Extended-Release Oral Minoxidil
Veradermics is working on FDA approval for extended-release oral Minoxidil. Approval is expected around 2027.
community I’m taking Veradermics VDPHL01 - AMA
A participant using Veradermics VDPHL01, an extended-release oral minoxidil, experienced significant hair regrowth from Norwood 6 to Norwood 3V without side effects. They plan to use dutasteride after the treatment to maintain results.
community Veradermics VDPHL01: why isn’t anyone talking about it?
Veradermics' new hair loss treatment, VDPHL01, is likely a modified release oral minoxidil, which has received $75 million in funding for clinical trials. Despite skepticism about investing in a known treatment, some believe it could offer improved efficacy and reduced side effects.
Related Research
6 / 6 resultsresearch Emerging pharmacotherapies and regenerative solutions for promoting hair growth for androgenetic alopecia
This study reviews new treatments for androgenetic alopecia, including cell-derived exosomes and investigational drugs, which show potential to improve hair density and quality but require more rigorous and standardized trials to confirm efficacy and safety.
research 76221 Faster Onset and Superior Efficacy of an Investigational Extended-Release Oral Minoxidil Tablet (VDPHL01) Versus Topical and Immediate-Release Oral Minoxidil for Androgenetic Alopecia: Results from a Blinded Retrospective Investigator Global Assessment
research 76626 Adjunctive Combined Regenerative Technique (CRT) vs Oral Minoxidil Alone for Androgenetic Alopecia: A Six-Month Retrospective Study
CRT is more effective than oral minoxidil alone for treating hair loss.
research Beyond Minoxidil: Off-Label Therapies for Male Androgenetic Alopecia—A Systematic Review with Network Meta-Analyses
In this network meta-analysis, the researchers reported that topical minoxidil 5% was the most effective off-label therapy for increasing hair density in men with androgenetic alopecia, while other treatments like melatonin and cetirizine showed potential benefits, highlighting a need for further comparative trials.
research Three months extended-release microspheres prepared by multi-microchannel microfluidics in beagle dog models
This study demonstrated that finasteride-loaded PLGA microspheres created using a novel microfluidic device exhibit extended drug release in beagle dogs, with modifications allowing for release up to 3 months.
research Effect of metformin by employing 2-hour postload insulin for measuring insulin resistance in Taiwanese women with polycystic ovary syndrome
This study found that metformin treatment improved clinical outcomes in Taiwanese women with polycystic ovary syndrome, notably in overweight and insulin-resistant patients.